Amicus Therapeutics, Inc.

Amicus Therapeutics Beats on EPS, Stock Up 5.5%

Amicus Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 5.5%. However, there was no revenue reported, and no guidance was provided for future performance. Investors may be cautiously optimistic about the EPS beat, but the lack of revenue and guidance leaves uncertainty about the company's growth prospects.